2vio - Revision history

OCA at 10:45, 7 July 2021

OCA — Wed, 07 Jul 2021 10:45:55 GMT

←Older revision		Revision as of 10:45, 7 July 2021
Line 3:		Line 3:
	<StructureSection load='2vio' size='340' side='right'caption='[[2vio]], [[Resolution\|resolution]] 1.80Å' scene=''>		<StructureSection load='2vio' size='340' side='right'caption='[[2vio]], [[Resolution\|resolution]] 1.80Å' scene=''>
	== Structural highlights ==		== Structural highlights ==
-	<table><tr><td colspan='2'>[[2vio]] is a 1 chain structure with sequence from [~~http~~://en.wikipedia.org/wiki/Human Human]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=2VIO OCA]. For a <b>guided tour on the structure components</b> use [~~http~~://~~oca~~.~~weizmann.ac.il/oca-docs~~/fgij/fg.htm?mol=2VIO FirstGlance]. <br>	+	<table><tr><td colspan='2'>[[2vio]] is a 1 chain structure with sequence from [https://en.wikipedia.org/wiki/Human Human]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=2VIO OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=2VIO FirstGlance]. <br>
-	</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=ACT:ACETATE+ION'>ACT</scene>, <scene name='pdbligand=L1O:4-(2-AMINOETHOXY)-3,5-DICHLOROBENZOIC+ACID'>L1O</scene></td></tr>	+	</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=ACT:ACETATE+ION'>ACT</scene>, <scene name='pdbligand=L1O:4-(2-AMINOETHOXY)-3,5-DICHLOROBENZOIC+ACID'>L1O</scene></td></tr>
-	<tr id='related'><td class="sblockLbl"><b>[[Related_structure\|Related:]]</b></td><td class="sblockDat">[[1c5x\|1c5x]], [[1gj9\|1gj9]], [[1w0z\|1w0z]], [[1fv9\|1fv9]], [[1vja\|1vja]], [[1gj8\|1gj8]], [[1w11\|1w11]], [[1sqo\|1sqo]], [[1gjd\|1gjd]], [[1w10\|1w10]], [[1owk\|1owk]], [[1w12\|1w12]], [[1gi9\|1gi9]], [[1o5a\|1o5a]], [[1c5z\|1c5z]], [[1owj\|1owj]], [[1gi7\|1gi7]], [[1o5b\|1o5b]], [[1gjc\|1gjc]], [[1sc8\|1sc8]], [[1gja\|1gja]], [[1o3p\|1o3p]], [[1owe\|1owe]], [[1sqa\|1sqa]], [[1gjb\|1gjb]], [[1f92\|1f92]], [[1owi\|1owi]], [[1kdu\|1kdu]], [[1sqt\|1sqt]], [[1f5l\|1f5l]], [[1owd\|1owd]], [[1ejn\|1ejn]], [[1lmw\|1lmw]], [[1u6q\|1u6q]], [[1gi8\|1gi8]], [[2jde\|2jde]], [[1c5y\|1c5y]], [[1w14\|1w14]], [[1vj9\|1vj9]], [[1w13\|1w13]], [[1gj7\|1gj7]], [[1c5w\|1c5w]], [[1owh\|1owh]], [[1o5c\|1o5c]], [[2vin\|2vin]], [[2vip\|2vip]], [[2viq\|2viq]], [[2viv\|2viv]], [[2viw\|2viw]]</td></tr>	+	<tr id='related'><td class="sblockLbl"><b>[[Related_structure\|Related:]]</b></td><td class="sblockDat"><div style='overflow: auto; max-height: 3em;'>[[1c5x\|1c5x]], [[1gj9\|1gj9]], [[1w0z\|1w0z]], [[1fv9\|1fv9]], [[1vja\|1vja]], [[1gj8\|1gj8]], [[1w11\|1w11]], [[1sqo\|1sqo]], [[1gjd\|1gjd]], [[1w10\|1w10]], [[1owk\|1owk]], [[1w12\|1w12]], [[1gi9\|1gi9]], [[1o5a\|1o5a]], [[1c5z\|1c5z]], [[1owj\|1owj]], [[1gi7\|1gi7]], [[1o5b\|1o5b]], [[1gjc\|1gjc]], [[1sc8\|1sc8]], [[1gja\|1gja]], [[1o3p\|1o3p]], [[1owe\|1owe]], [[1sqa\|1sqa]], [[1gjb\|1gjb]], [[1f92\|1f92]], [[1owi\|1owi]], [[1kdu\|1kdu]], [[1sqt\|1sqt]], [[1f5l\|1f5l]], [[1owd\|1owd]], [[1ejn\|1ejn]], [[1lmw\|1lmw]], [[1u6q\|1u6q]], [[1gi8\|1gi8]], [[2jde\|2jde]], [[1c5y\|1c5y]], [[1w14\|1w14]], [[1vj9\|1vj9]], [[1w13\|1w13]], [[1gj7\|1gj7]], [[1c5w\|1c5w]], [[1owh\|1owh]], [[1o5c\|1o5c]], [[2vin\|2vin]], [[2vip\|2vip]], [[2viq\|2viq]], [[2viv\|2viv]], [[2viw\|2viw]]</div></td></tr>
-	<tr id='activity'><td class="sblockLbl"><b>Activity:</b></td><td class="sblockDat"><span class='plainlinks'>[~~http~~://en.wikipedia.org/wiki/U-plasminogen_activator U-plasminogen activator], with EC number [~~http~~://www.brenda-enzymes.info/php/result_flat.php4?ecno=3.4.21.73 3.4.21.73] </span></td></tr>	+	<tr id='activity'><td class="sblockLbl"><b>Activity:</b></td><td class="sblockDat"><span class='plainlinks'>[https://en.wikipedia.org/wiki/U-plasminogen_activator U-plasminogen activator], with EC number [https://www.brenda-enzymes.info/php/result_flat.php4?ecno=3.4.21.73 3.4.21.73] </span></td></tr>
-	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[~~http~~://~~oca~~.~~weizmann.ac.il/oca-docs~~/fgij/fg.htm?mol=2vio FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=2vio OCA], [~~http~~://pdbe.org/2vio PDBe], [~~http~~://www.rcsb.org/pdb/explore.do?structureId=2vio RCSB], [~~http~~://www.ebi.ac.uk/pdbsum/2vio PDBsum], [~~http~~://prosat.h-its.org/prosat/prosatexe?pdbcode=2vio ProSAT]</span></td></tr>	+	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=2vio FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=2vio OCA], [https://pdbe.org/2vio PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=2vio RCSB], [https://www.ebi.ac.uk/pdbsum/2vio PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=2vio ProSAT]</span></td></tr>
	</table>		</table>
	== Disease ==		== Disease ==
-	[[~~http~~://www.uniprot.org/uniprot/UROK_HUMAN UROK_HUMAN]] Defects in PLAU are the cause of Quebec platelet disorder (QPD) [MIM:[~~http~~://omim.org/entry/601709 601709]]. QPD is an autosomal dominant bleeding disorder due to a gain-of-function defect in fibrinolysis. Although affected individuals do not exhibit systemic fibrinolysis, they show delayed onset bleeding after challenge, such as surgery. The hallmark of the disorder is markedly increased PLAU levels within platelets, which causes intraplatelet plasmin generation and secondary degradation of alpha-granule proteins.<ref>PMID:20007542</ref>	+	[[https://www.uniprot.org/uniprot/UROK_HUMAN UROK_HUMAN]] Defects in PLAU are the cause of Quebec platelet disorder (QPD) [MIM:[https://omim.org/entry/601709 601709]]. QPD is an autosomal dominant bleeding disorder due to a gain-of-function defect in fibrinolysis. Although affected individuals do not exhibit systemic fibrinolysis, they show delayed onset bleeding after challenge, such as surgery. The hallmark of the disorder is markedly increased PLAU levels within platelets, which causes intraplatelet plasmin generation and secondary degradation of alpha-granule proteins.<ref>PMID:20007542</ref>
	== Function ==		== Function ==
-	[[~~http~~://www.uniprot.org/uniprot/UROK_HUMAN UROK_HUMAN]] Specifically cleaves the zymogen plasminogen to form the active enzyme plasmin.	+	[[https://www.uniprot.org/uniprot/UROK_HUMAN UROK_HUMAN]] Specifically cleaves the zymogen plasminogen to form the active enzyme plasmin.
	== Evolutionary Conservation ==		== Evolutionary Conservation ==
	[[Image:Consurf_key_small.gif\|200px\|right]]		[[Image:Consurf_key_small.gif\|200px\|right]]
Line 34:		Line 34:

	==See Also==		==See Also==
-	*[[Urokinase\|Urokinase]]	+	*[[Urokinase 3D Structures\|Urokinase 3D Structures]]
	== References ==		== References ==
	<references/>		<references/>

OCA at 07:18, 21 August 2019

OCA — Wed, 21 Aug 2019 07:18:20 GMT

←Older revision		Revision as of 07:18, 21 August 2019
Line 1:		Line 1:

	==Fragment-Based Discovery of Mexiletine Derivatives as Orally Bioavailable Inhibitors of Urokinase-Type Plasminogen Activator==		==Fragment-Based Discovery of Mexiletine Derivatives as Orally Bioavailable Inhibitors of Urokinase-Type Plasminogen Activator==
-	<StructureSection load='2vio' size='340' side='right' caption='[[2vio]], [[Resolution\|resolution]] 1.80Å' scene=''>	+	<StructureSection load='2vio' size='340' side='right'caption='[[2vio]], [[Resolution\|resolution]] 1.80Å' scene=''>
	== Structural highlights ==		== Structural highlights ==
	<table><tr><td colspan='2'>[[2vio]] is a 1 chain structure with sequence from [http://en.wikipedia.org/wiki/Human Human]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=2VIO OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=2VIO FirstGlance]. <br>		<table><tr><td colspan='2'>[[2vio]] is a 1 chain structure with sequence from [http://en.wikipedia.org/wiki/Human Human]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=2VIO OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=2VIO FirstGlance]. <br>
Line 17:		Line 17:
	Check<jmol>		Check<jmol>
	<jmolCheckbox>		<jmolCheckbox>
-	<scriptWhenChecked>select protein; define ~consurf_to_do selected; consurf_initial_scene = true; script "/wiki/ConSurf/vi/2vio_consurf.spt"</scriptWhenChecked>	+	<scriptWhenChecked>; select protein; define ~consurf_to_do selected; consurf_initial_scene = true; script "/wiki/ConSurf/vi/2vio_consurf.spt"</scriptWhenChecked>
	<scriptWhenUnchecked>script /wiki/extensions/Proteopedia/spt/initialview01.spt</scriptWhenUnchecked>		<scriptWhenUnchecked>script /wiki/extensions/Proteopedia/spt/initialview01.spt</scriptWhenUnchecked>
	<text>to colour the structure by Evolutionary Conservation</text>		<text>to colour the structure by Evolutionary Conservation</text>
Line 32:		Line 32:
	</div>		</div>
	<div class="pdbe-citations 2vio" style="background-color:#fffaf0;"></div>		<div class="pdbe-citations 2vio" style="background-color:#fffaf0;"></div>
		+
		+	==See Also==
		+	*[[Urokinase\|Urokinase]]
	== References ==		== References ==
	<references/>		<references/>
Line 37:		Line 40:
	</StructureSection>		</StructureSection>
	[[Category: Human]]		[[Category: Human]]
		+	[[Category: Large Structures]]
	[[Category: U-plasminogen activator]]		[[Category: U-plasminogen activator]]
	[[Category: Callaghan, O]]		[[Category: Callaghan, O]]

OCA at 07:25, 16 November 2017

OCA — Thu, 16 Nov 2017 07:25:02 GMT

←Older revision		Revision as of 07:25, 16 November 2017
Line 1:		Line 1:

-	==~~FRAGMENT~~-~~BASED DISCOVERY OF MEXILETINE DERIVATIVES AS ORALLY BIOAVAILABLE INHIBITORS OF UROKINASE~~-~~TYPE PLASMINOGEN ACTIVATOR~~==	+	==Fragment-Based Discovery of Mexiletine Derivatives as Orally Bioavailable Inhibitors of Urokinase-Type Plasminogen Activator==
	<StructureSection load='2vio' size='340' side='right' caption='[[2vio]], [[Resolution\|resolution]] 1.80Å' scene=''>		<StructureSection load='2vio' size='340' side='right' caption='[[2vio]], [[Resolution\|resolution]] 1.80Å' scene=''>
	== Structural highlights ==		== Structural highlights ==
Line 32:		Line 32:
	</div>		</div>
	<div class="pdbe-citations 2vio" style="background-color:#fffaf0;"></div>		<div class="pdbe-citations 2vio" style="background-color:#fffaf0;"></div>
-
-	==See Also==
-	*[[Urokinase\|Urokinase]]
	== References ==		== References ==
	<references/>		<references/>
Line 47:		Line 44:
	[[Category: Frederickson, M]]		[[Category: Frederickson, M]]
	[[Category: Matthews, J E]]		[[Category: Matthews, J E]]
-	[[Category: ~~Mcmenamin~~, R]]	+	[[Category: McMenamin, R]]
	[[Category: Smith, D]]		[[Category: Smith, D]]
	[[Category: Vinkovic, M]]		[[Category: Vinkovic, M]]
Line 58:		Line 55:
	[[Category: Inhibitor]]		[[Category: Inhibitor]]
	[[Category: Kringle]]		[[Category: Kringle]]
		+	[[Category: Pharmaceutical]]
	[[Category: Phosphorylation]]		[[Category: Phosphorylation]]
	[[Category: Plasminogen activation]]		[[Category: Plasminogen activation]]
		+	[[Category: Polymorphism]]
	[[Category: Protease]]		[[Category: Protease]]
	[[Category: Secreted]]		[[Category: Secreted]]

OCA at 10:05, 11 August 2016

OCA — Thu, 11 Aug 2016 10:05:52 GMT

←Older revision		Revision as of 10:05, 11 August 2016
Line 1:		Line 1:
		+
	==FRAGMENT-BASED DISCOVERY OF MEXILETINE DERIVATIVES AS ORALLY BIOAVAILABLE INHIBITORS OF UROKINASE-TYPE PLASMINOGEN ACTIVATOR==		==FRAGMENT-BASED DISCOVERY OF MEXILETINE DERIVATIVES AS ORALLY BIOAVAILABLE INHIBITORS OF UROKINASE-TYPE PLASMINOGEN ACTIVATOR==
	<StructureSection load='2vio' size='340' side='right' caption='[[2vio]], [[Resolution\|resolution]] 1.80Å' scene=''>		<StructureSection load='2vio' size='340' side='right' caption='[[2vio]], [[Resolution\|resolution]] 1.80Å' scene=''>
	== Structural highlights ==		== Structural highlights ==
-	<table><tr><td colspan='2'>[[2vio]] is a 1 chain structure with sequence from [http://en.wikipedia.org/wiki/~~Homo_sapiens Homo sapiens~~]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=2VIO OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=2VIO FirstGlance]. <br>	+	<table><tr><td colspan='2'>[[2vio]] is a 1 chain structure with sequence from [http://en.wikipedia.org/wiki/Human Human]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=2VIO OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=2VIO FirstGlance]. <br>
	</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=ACT:ACETATE+ION'>ACT</scene>, <scene name='pdbligand=L1O:4-(2-AMINOETHOXY)-3,5-DICHLOROBENZOIC+ACID'>L1O</scene></td></tr>		</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=ACT:ACETATE+ION'>ACT</scene>, <scene name='pdbligand=L1O:4-(2-AMINOETHOXY)-3,5-DICHLOROBENZOIC+ACID'>L1O</scene></td></tr>
	<tr id='related'><td class="sblockLbl"><b>[[Related_structure\|Related:]]</b></td><td class="sblockDat">[[1c5x\|1c5x]], [[1gj9\|1gj9]], [[1w0z\|1w0z]], [[1fv9\|1fv9]], [[1vja\|1vja]], [[1gj8\|1gj8]], [[1w11\|1w11]], [[1sqo\|1sqo]], [[1gjd\|1gjd]], [[1w10\|1w10]], [[1owk\|1owk]], [[1w12\|1w12]], [[1gi9\|1gi9]], [[1o5a\|1o5a]], [[1c5z\|1c5z]], [[1owj\|1owj]], [[1gi7\|1gi7]], [[1o5b\|1o5b]], [[1gjc\|1gjc]], [[1sc8\|1sc8]], [[1gja\|1gja]], [[1o3p\|1o3p]], [[1owe\|1owe]], [[1sqa\|1sqa]], [[1gjb\|1gjb]], [[1f92\|1f92]], [[1owi\|1owi]], [[1kdu\|1kdu]], [[1sqt\|1sqt]], [[1f5l\|1f5l]], [[1owd\|1owd]], [[1ejn\|1ejn]], [[1lmw\|1lmw]], [[1u6q\|1u6q]], [[1gi8\|1gi8]], [[2jde\|2jde]], [[1c5y\|1c5y]], [[1w14\|1w14]], [[1vj9\|1vj9]], [[1w13\|1w13]], [[1gj7\|1gj7]], [[1c5w\|1c5w]], [[1owh\|1owh]], [[1o5c\|1o5c]], [[2vin\|2vin]], [[2vip\|2vip]], [[2viq\|2viq]], [[2viv\|2viv]], [[2viw\|2viw]]</td></tr>		<tr id='related'><td class="sblockLbl"><b>[[Related_structure\|Related:]]</b></td><td class="sblockDat">[[1c5x\|1c5x]], [[1gj9\|1gj9]], [[1w0z\|1w0z]], [[1fv9\|1fv9]], [[1vja\|1vja]], [[1gj8\|1gj8]], [[1w11\|1w11]], [[1sqo\|1sqo]], [[1gjd\|1gjd]], [[1w10\|1w10]], [[1owk\|1owk]], [[1w12\|1w12]], [[1gi9\|1gi9]], [[1o5a\|1o5a]], [[1c5z\|1c5z]], [[1owj\|1owj]], [[1gi7\|1gi7]], [[1o5b\|1o5b]], [[1gjc\|1gjc]], [[1sc8\|1sc8]], [[1gja\|1gja]], [[1o3p\|1o3p]], [[1owe\|1owe]], [[1sqa\|1sqa]], [[1gjb\|1gjb]], [[1f92\|1f92]], [[1owi\|1owi]], [[1kdu\|1kdu]], [[1sqt\|1sqt]], [[1f5l\|1f5l]], [[1owd\|1owd]], [[1ejn\|1ejn]], [[1lmw\|1lmw]], [[1u6q\|1u6q]], [[1gi8\|1gi8]], [[2jde\|2jde]], [[1c5y\|1c5y]], [[1w14\|1w14]], [[1vj9\|1vj9]], [[1w13\|1w13]], [[1gj7\|1gj7]], [[1c5w\|1c5w]], [[1owh\|1owh]], [[1o5c\|1o5c]], [[2vin\|2vin]], [[2vip\|2vip]], [[2viq\|2viq]], [[2viv\|2viv]], [[2viw\|2viw]]</td></tr>
	<tr id='activity'><td class="sblockLbl"><b>Activity:</b></td><td class="sblockDat"><span class='plainlinks'>[http://en.wikipedia.org/wiki/U-plasminogen_activator U-plasminogen activator], with EC number [http://www.brenda-enzymes.info/php/result_flat.php4?ecno=3.4.21.73 3.4.21.73] </span></td></tr>		<tr id='activity'><td class="sblockLbl"><b>Activity:</b></td><td class="sblockDat"><span class='plainlinks'>[http://en.wikipedia.org/wiki/U-plasminogen_activator U-plasminogen activator], with EC number [http://www.brenda-enzymes.info/php/result_flat.php4?ecno=3.4.21.73 3.4.21.73] </span></td></tr>
-	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=2vio FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=2vio OCA], [http://www.rcsb.org/pdb/explore.do?structureId=2vio RCSB], [http://www.ebi.ac.uk/pdbsum/2vio PDBsum]</span></td></tr>	+	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=2vio FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=2vio OCA], [http://pdbe.org/2vio PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=2vio RCSB], [http://www.ebi.ac.uk/pdbsum/2vio PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=2vio ProSAT]</span></td></tr>
	</table>		</table>
	== Disease ==		== Disease ==
Line 20:		Line 21:
	<text>to colour the structure by Evolutionary Conservation</text>		<text>to colour the structure by Evolutionary Conservation</text>
	</jmolCheckbox>		</jmolCheckbox>
-	</jmol>, as determined by [http://consurfdb.tau.ac.il/ ConSurfDB]. You may read the [[Conservation%2C_Evolutionary\|explanation]] of the method and the full data available from [http://bental.tau.ac.il/new_ConSurfDB/~~chain_selection~~.php?pdb_ID=~~2ata~~ ConSurf].	+	</jmol>, as determined by [http://consurfdb.tau.ac.il/ ConSurfDB]. You may read the [[Conservation%2C_Evolutionary\|explanation]] of the method and the full data available from [http://bental.tau.ac.il/new_ConSurfDB/main_output.php?pdb_ID=2vio ConSurf].
	<div style="clear:both"></div>		<div style="clear:both"></div>
	<div style="background-color:#fffaf0;">		<div style="background-color:#fffaf0;">
Line 30:		Line 31:
	From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br>		From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br>
	</div>		</div>
		+	<div class="pdbe-citations 2vio" style="background-color:#fffaf0;"></div>

	==See Also==		==See Also==
Line 37:		Line 39:
	__TOC__		__TOC__
	</StructureSection>		</StructureSection>
-	[[Category: ~~Homo sapiens~~]]	+	[[Category: Human]]
	[[Category: U-plasminogen activator]]		[[Category: U-plasminogen activator]]
	[[Category: Callaghan, O]]		[[Category: Callaghan, O]]

OCA at 17:31, 19 January 2015

OCA — Mon, 19 Jan 2015 17:31:40 GMT

←Older revision		Revision as of 17:31, 19 January 2015
Line 3:		Line 3:
	== Structural highlights ==		== Structural highlights ==
	<table><tr><td colspan='2'>[[2vio]] is a 1 chain structure with sequence from [http://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=2VIO OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=2VIO FirstGlance]. <br>		<table><tr><td colspan='2'>[[2vio]] is a 1 chain structure with sequence from [http://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=2VIO OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=2VIO FirstGlance]. <br>
-	</td></tr><tr><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=ACT:ACETATE+ION'>ACT</scene>, <scene name='pdbligand=L1O:4-(2-AMINOETHOXY)-3,5-DICHLOROBENZOIC+ACID'>L1O</scene><br>	+	</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=ACT:ACETATE+ION'>ACT</scene>, <scene name='pdbligand=L1O:4-(2-AMINOETHOXY)-3,5-DICHLOROBENZOIC+ACID'>L1O</scene></td></tr>
-	<tr><td class="sblockLbl"><b>[[Related_structure\|Related:]]</b></td><td class="sblockDat">[[1c5x\|1c5x]], [[1gj9\|1gj9]], [[1w0z\|1w0z]], [[1fv9\|1fv9]], [[1vja\|1vja]], [[1gj8\|1gj8]], [[1w11\|1w11]], [[1sqo\|1sqo]], [[1gjd\|1gjd]], [[1w10\|1w10]], [[1owk\|1owk]], [[1w12\|1w12]], [[1gi9\|1gi9]], [[1o5a\|1o5a]], [[1c5z\|1c5z]], [[1owj\|1owj]], [[1gi7\|1gi7]], [[1o5b\|1o5b]], [[1gjc\|1gjc]], [[1sc8\|1sc8]], [[1gja\|1gja]], [[1o3p\|1o3p]], [[1owe\|1owe]], [[1sqa\|1sqa]], [[1gjb\|1gjb]], [[1f92\|1f92]], [[1owi\|1owi]], [[1kdu\|1kdu]], [[1sqt\|1sqt]], [[1f5l\|1f5l]], [[1owd\|1owd]], [[1ejn\|1ejn]], [[1lmw\|1lmw]], [[1u6q\|1u6q]], [[1gi8\|1gi8]], [[2jde\|2jde]], [[1c5y\|1c5y]], [[1w14\|1w14]], [[1vj9\|1vj9]], [[1w13\|1w13]], [[1gj7\|1gj7]], [[1c5w\|1c5w]], [[1owh\|1owh]], [[1o5c\|1o5c]], [[2vin\|2vin]], [[2vip\|2vip]], [[2viq\|2viq]], [[2viv\|2viv]], [[2viw\|2viw]]</td></tr>	+	<tr id='related'><td class="sblockLbl"><b>[[Related_structure\|Related:]]</b></td><td class="sblockDat">[[1c5x\|1c5x]], [[1gj9\|1gj9]], [[1w0z\|1w0z]], [[1fv9\|1fv9]], [[1vja\|1vja]], [[1gj8\|1gj8]], [[1w11\|1w11]], [[1sqo\|1sqo]], [[1gjd\|1gjd]], [[1w10\|1w10]], [[1owk\|1owk]], [[1w12\|1w12]], [[1gi9\|1gi9]], [[1o5a\|1o5a]], [[1c5z\|1c5z]], [[1owj\|1owj]], [[1gi7\|1gi7]], [[1o5b\|1o5b]], [[1gjc\|1gjc]], [[1sc8\|1sc8]], [[1gja\|1gja]], [[1o3p\|1o3p]], [[1owe\|1owe]], [[1sqa\|1sqa]], [[1gjb\|1gjb]], [[1f92\|1f92]], [[1owi\|1owi]], [[1kdu\|1kdu]], [[1sqt\|1sqt]], [[1f5l\|1f5l]], [[1owd\|1owd]], [[1ejn\|1ejn]], [[1lmw\|1lmw]], [[1u6q\|1u6q]], [[1gi8\|1gi8]], [[2jde\|2jde]], [[1c5y\|1c5y]], [[1w14\|1w14]], [[1vj9\|1vj9]], [[1w13\|1w13]], [[1gj7\|1gj7]], [[1c5w\|1c5w]], [[1owh\|1owh]], [[1o5c\|1o5c]], [[2vin\|2vin]], [[2vip\|2vip]], [[2viq\|2viq]], [[2viv\|2viv]], [[2viw\|2viw]]</td></tr>
-	<tr><td class="sblockLbl"><b>Activity:</b></td><td class="sblockDat"><span class='plainlinks'>[http://en.wikipedia.org/wiki/U-plasminogen_activator U-plasminogen activator], with EC number [http://www.brenda-enzymes.info/php/result_flat.php4?ecno=3.4.21.73 3.4.21.73] </span></td></tr>	+	<tr id='activity'><td class="sblockLbl"><b>Activity:</b></td><td class="sblockDat"><span class='plainlinks'>[http://en.wikipedia.org/wiki/U-plasminogen_activator U-plasminogen activator], with EC number [http://www.brenda-enzymes.info/php/result_flat.php4?ecno=3.4.21.73 3.4.21.73] </span></td></tr>
-	<tr><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=2vio FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=2vio OCA], [http://www.rcsb.org/pdb/explore.do?structureId=2vio RCSB], [http://www.ebi.ac.uk/pdbsum/2vio PDBsum]</span></td></tr>	+	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=2vio FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=2vio OCA], [http://www.rcsb.org/pdb/explore.do?structureId=2vio RCSB], [http://www.ebi.ac.uk/pdbsum/2vio PDBsum]</span></td></tr>
-	<table>	+	</table>
	== Disease ==		== Disease ==
	[[http://www.uniprot.org/uniprot/UROK_HUMAN UROK_HUMAN]] Defects in PLAU are the cause of Quebec platelet disorder (QPD) [MIM:[http://omim.org/entry/601709 601709]]. QPD is an autosomal dominant bleeding disorder due to a gain-of-function defect in fibrinolysis. Although affected individuals do not exhibit systemic fibrinolysis, they show delayed onset bleeding after challenge, such as surgery. The hallmark of the disorder is markedly increased PLAU levels within platelets, which causes intraplatelet plasmin generation and secondary degradation of alpha-granule proteins.<ref>PMID:20007542</ref>		[[http://www.uniprot.org/uniprot/UROK_HUMAN UROK_HUMAN]] Defects in PLAU are the cause of Quebec platelet disorder (QPD) [MIM:[http://omim.org/entry/601709 601709]]. QPD is an autosomal dominant bleeding disorder due to a gain-of-function defect in fibrinolysis. Although affected individuals do not exhibit systemic fibrinolysis, they show delayed onset bleeding after challenge, such as surgery. The hallmark of the disorder is markedly increased PLAU levels within platelets, which causes intraplatelet plasmin generation and secondary degradation of alpha-granule proteins.<ref>PMID:20007542</ref>
Line 39:		Line 39:
	[[Category: Homo sapiens]]		[[Category: Homo sapiens]]
	[[Category: U-plasminogen activator]]		[[Category: U-plasminogen activator]]
-	[[Category: Callaghan, O.]]	+	[[Category: Callaghan, O]]
-	[[Category: Chessari, G.]]	+	[[Category: Chessari, G]]
-	[[Category: Congreve, M.]]	+	[[Category: Congreve, M]]
-	[[Category: Cowan, S R.]]	+	[[Category: Cowan, S R]]
-	[[Category: Frederickson, M.]]	+	[[Category: Frederickson, M]]
-	[[Category: Matthews, J E.]]	+	[[Category: Matthews, J E]]
-	[[Category: Mcmenamin, R.]]	+	[[Category: Mcmenamin, R]]
-	[[Category: Smith, D.]]	+	[[Category: Smith, D]]
-	[[Category: Vinkovic, M.]]	+	[[Category: Vinkovic, M]]
-	[[Category: Wallis, N G.]]	+	[[Category: Wallis, N G]]
	[[Category: Blood coagulation]]		[[Category: Blood coagulation]]
	[[Category: Egf-like domain]]		[[Category: Egf-like domain]]

OCA at 01:56, 1 October 2014

OCA — Wed, 01 Oct 2014 01:56:45 GMT

←Older revision		Revision as of 01:56, 1 October 2014
Line 1:		Line 1:
-	~~{{STRUCTURE_2vio\| PDB=2vio \| SCENE= }}~~	+	==FRAGMENT-BASED DISCOVERY OF MEXILETINE DERIVATIVES AS ORALLY BIOAVAILABLE INHIBITORS OF UROKINASE-TYPE PLASMINOGEN ACTIVATOR==
-	===FRAGMENT-BASED DISCOVERY OF MEXILETINE DERIVATIVES AS ORALLY BIOAVAILABLE INHIBITORS OF UROKINASE-TYPE PLASMINOGEN ACTIVATOR===	+	<StructureSection load='2vio' size='340' side='right' caption='[[2vio]], [[Resolution\|resolution]] 1.80Å' scene=''>
-	~~{{ABSTRACT_PUBMED_18163548}}~~	+	== Structural highlights ==
		+	<table><tr><td colspan='2'>[[2vio]] is a 1 chain structure with sequence from [http://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=2VIO OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=2VIO FirstGlance]. <br>
		+	</td></tr><tr><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=ACT:ACETATE+ION'>ACT</scene>, <scene name='pdbligand=L1O:4-(2-AMINOETHOXY)-3,5-DICHLOROBENZOIC+ACID'>L1O</scene><br>
		+	<tr><td class="sblockLbl"><b>[[Related_structure\|Related:]]</b></td><td class="sblockDat">[[1c5x\|1c5x]], [[1gj9\|1gj9]], [[1w0z\|1w0z]], [[1fv9\|1fv9]], [[1vja\|1vja]], [[1gj8\|1gj8]], [[1w11\|1w11]], [[1sqo\|1sqo]], [[1gjd\|1gjd]], [[1w10\|1w10]], [[1owk\|1owk]], [[1w12\|1w12]], [[1gi9\|1gi9]], [[1o5a\|1o5a]], [[1c5z\|1c5z]], [[1owj\|1owj]], [[1gi7\|1gi7]], [[1o5b\|1o5b]], [[1gjc\|1gjc]], [[1sc8\|1sc8]], [[1gja\|1gja]], [[1o3p\|1o3p]], [[1owe\|1owe]], [[1sqa\|1sqa]], [[1gjb\|1gjb]], [[1f92\|1f92]], [[1owi\|1owi]], [[1kdu\|1kdu]], [[1sqt\|1sqt]], [[1f5l\|1f5l]], [[1owd\|1owd]], [[1ejn\|1ejn]], [[1lmw\|1lmw]], [[1u6q\|1u6q]], [[1gi8\|1gi8]], [[2jde\|2jde]], [[1c5y\|1c5y]], [[1w14\|1w14]], [[1vj9\|1vj9]], [[1w13\|1w13]], [[1gj7\|1gj7]], [[1c5w\|1c5w]], [[1owh\|1owh]], [[1o5c\|1o5c]], [[2vin\|2vin]], [[2vip\|2vip]], [[2viq\|2viq]], [[2viv\|2viv]], [[2viw\|2viw]]</td></tr>
		+	<tr><td class="sblockLbl"><b>Activity:</b></td><td class="sblockDat"><span class='plainlinks'>[http://en.wikipedia.org/wiki/U-plasminogen_activator U-plasminogen activator], with EC number [http://www.brenda-enzymes.info/php/result_flat.php4?ecno=3.4.21.73 3.4.21.73] </span></td></tr>
		+	<tr><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=2vio FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=2vio OCA], [http://www.rcsb.org/pdb/explore.do?structureId=2vio RCSB], [http://www.ebi.ac.uk/pdbsum/2vio PDBsum]</span></td></tr>
		+	<table>
		+	== Disease ==
		+	[[http://www.uniprot.org/uniprot/UROK_HUMAN UROK_HUMAN]] Defects in PLAU are the cause of Quebec platelet disorder (QPD) [MIM:[http://omim.org/entry/601709 601709]]. QPD is an autosomal dominant bleeding disorder due to a gain-of-function defect in fibrinolysis. Although affected individuals do not exhibit systemic fibrinolysis, they show delayed onset bleeding after challenge, such as surgery. The hallmark of the disorder is markedly increased PLAU levels within platelets, which causes intraplatelet plasmin generation and secondary degradation of alpha-granule proteins.<ref>PMID:20007542</ref>
		+	== Function ==
		+	[[http://www.uniprot.org/uniprot/UROK_HUMAN UROK_HUMAN]] Specifically cleaves the zymogen plasminogen to form the active enzyme plasmin.
		+	== Evolutionary Conservation ==
		+	[[Image:Consurf_key_small.gif\|200px\|right]]
		+	Check<jmol>
		+	<jmolCheckbox>
		+	<scriptWhenChecked>select protein; define ~consurf_to_do selected; consurf_initial_scene = true; script "/wiki/ConSurf/vi/2vio_consurf.spt"</scriptWhenChecked>
		+	<scriptWhenUnchecked>script /wiki/extensions/Proteopedia/spt/initialview01.spt</scriptWhenUnchecked>
		+	<text>to colour the structure by Evolutionary Conservation</text>
		+	</jmolCheckbox>
		+	</jmol>, as determined by [http://consurfdb.tau.ac.il/ ConSurfDB]. You may read the [[Conservation%2C_Evolutionary\|explanation]] of the method and the full data available from [http://bental.tau.ac.il/new_ConSurfDB/chain_selection.php?pdb_ID=2ata ConSurf].
		+	<div style="clear:both"></div>
		+	<div style="background-color:#fffaf0;">
		+	== Publication Abstract from PubMed ==
		+	Fragment-based lead discovery has been applied to urokinase-type plasminogen activator (uPA). The (R)-enantiomer of the orally active drug mexiletine 5 (a fragment hit from X-ray crystallographic screening) was the chemical starting point. Structure-aided design led to elaborated inhibitors that retained the key interactions of (R)-5 while gaining extra potency by simultaneously occupying neighboring regions of the active site. Subsequent optimization led to 15, a potent, selective, and orally bioavailable inhibitor of uPA.

-	~~==Disease==~~	+	Fragment-based discovery of mexiletine derivatives as orally bioavailable inhibitors of urokinase-type plasminogen activator.,Frederickson M, Callaghan O, Chessari G, Congreve M, Cowan SR, Matthews JE, McMenamin R, Smith DM, Vinkovic M, Wallis NG J Med Chem. 2008 Jan 24;51(2):183-6. Epub 2007 Dec 29. PMID:18163548<ref>PMID:18163548</ref>
-	[[http://www.uniprot.org/uniprot/UROK_HUMAN UROK_HUMAN]] Defects in PLAU are the cause of Quebec platelet disorder (QPD) [MIM:[http://omim.org/entry/601709 601709]]. QPD is an autosomal dominant bleeding disorder due to a gain-of-~~function defect in fibrinolysis~~. ~~Although affected individuals do not exhibit systemic fibrinolysis~~, ~~they show delayed onset bleeding after challenge~~, ~~such as surgery. The hallmark of the disorder is markedly increased PLAU levels within platelets~~, ~~which causes intraplatelet plasmin generation and secondary degradation of alpha~~-~~granule proteins~~.<ref>PMID:~~20007542~~</ref>	+

-	~~==Function==~~	+	From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br>
-	~~[[http:~~/~~/www~~.~~uniprot~~.~~org/uniprot/UROK_HUMAN UROK_HUMAN]] Specifically cleaves the zymogen plasminogen to form the active enzyme plasmin~~.	+	</div>
-		+
-	~~==About this Structure==~~	+
-	~~[[2vio]] is a 1 chain structure with sequence from [http:~~/~~/en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=2VIO OCA].~~	+

	==See Also==		==See Also==
	*[[Urokinase\|Urokinase]]		*[[Urokinase\|Urokinase]]
-		+	== References ==
-	==~~Reference~~==	+	<references/>
-	~~<ref group="xtra">PMID:018163548</ref>~~<references ~~group="xtra"~~/><~~references~~/>	+	__TOC__
		+	</StructureSection>
	[[Category: Homo sapiens]]		[[Category: Homo sapiens]]
	[[Category: U-plasminogen activator]]		[[Category: U-plasminogen activator]]

OCA at 17:20, 24 March 2013

OCA — Sun, 24 Mar 2013 17:20:38 GMT

←Older revision		Revision as of 17:20, 24 March 2013
Line 1:		Line 1:
-	[[Image:2vio.png\|left\|200px]]
-
	{{STRUCTURE_2vio\| PDB=2vio \| SCENE= }}		{{STRUCTURE_2vio\| PDB=2vio \| SCENE= }}
-
	===FRAGMENT-BASED DISCOVERY OF MEXILETINE DERIVATIVES AS ORALLY BIOAVAILABLE INHIBITORS OF UROKINASE-TYPE PLASMINOGEN ACTIVATOR===		===FRAGMENT-BASED DISCOVERY OF MEXILETINE DERIVATIVES AS ORALLY BIOAVAILABLE INHIBITORS OF UROKINASE-TYPE PLASMINOGEN ACTIVATOR===
		+	{{ABSTRACT_PUBMED_18163548}}

-	~~{{ABSTRACT_PUBMED_18163548}}~~	+	==Disease==
		+	[[http://www.uniprot.org/uniprot/UROK_HUMAN UROK_HUMAN]] Defects in PLAU are the cause of Quebec platelet disorder (QPD) [MIM:[http://omim.org/entry/601709 601709]]. QPD is an autosomal dominant bleeding disorder due to a gain-of-function defect in fibrinolysis. Although affected individuals do not exhibit systemic fibrinolysis, they show delayed onset bleeding after challenge, such as surgery. The hallmark of the disorder is markedly increased PLAU levels within platelets, which causes intraplatelet plasmin generation and secondary degradation of alpha-granule proteins.<ref>PMID:20007542</ref>
		+
		+	==Function==
		+	[[http://www.uniprot.org/uniprot/UROK_HUMAN UROK_HUMAN]] Specifically cleaves the zymogen plasminogen to form the active enzyme plasmin.

	==About this Structure==		==About this Structure==
Line 14:		Line 16:

	==Reference==		==Reference==
-	<ref group="xtra">PMID:018163548</ref><references group="xtra"/>	+	<ref group="xtra">PMID:018163548</ref><references group="xtra"/><references/>
	[[Category: Homo sapiens]]		[[Category: Homo sapiens]]
	[[Category: U-plasminogen activator]]		[[Category: U-plasminogen activator]]

OCA at 19:02, 20 October 2012

OCA — Sat, 20 Oct 2012 19:02:34 GMT

←Older revision		Revision as of 19:02, 20 October 2012
Line 8:		Line 8:

	==About this Structure==		==About this Structure==
-	[[2vio]] is a 1 chain structure ~~of [[Urokinase]]~~ with sequence from [http://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=2VIO OCA].	+	[[2vio]] is a 1 chain structure with sequence from [http://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=2VIO OCA].

	==See Also==		==See Also==

OCA: Protected "2vio" [edit=sysop:move=sysop]

OCA — Fri, 27 Jul 2012 06:05:13 GMT

Protected "2vio" [edit=sysop:move=sysop]

←Older revision

Revision as of 06:05, 27 July 2012

OCA at 06:05, 27 July 2012

OCA — Fri, 27 Jul 2012 06:05:12 GMT

←Older revision		Revision as of 06:05, 27 July 2012
Line 1:		Line 1:
-	{{Seed}}
	[[Image:2vio.png\|left\|200px]]		[[Image:2vio.png\|left\|200px]]

-	<!--
-	The line below this paragraph, containing "STRUCTURE_2vio", creates the "Structure Box" on the page.
-	You may change the PDB parameter (which sets the PDB file loaded into the applet)
-	or the SCENE parameter (which sets the initial scene displayed when the page is loaded),
-	or leave the SCENE parameter empty for the default display.
-	-->
	{{STRUCTURE_2vio\| PDB=2vio \| SCENE= }}		{{STRUCTURE_2vio\| PDB=2vio \| SCENE= }}

	===FRAGMENT-BASED DISCOVERY OF MEXILETINE DERIVATIVES AS ORALLY BIOAVAILABLE INHIBITORS OF UROKINASE-TYPE PLASMINOGEN ACTIVATOR===		===FRAGMENT-BASED DISCOVERY OF MEXILETINE DERIVATIVES AS ORALLY BIOAVAILABLE INHIBITORS OF UROKINASE-TYPE PLASMINOGEN ACTIVATOR===

-
-	<!--
-	The line below this paragraph, {{ABSTRACT_PUBMED_18163548}}, adds the Publication Abstract to the page
-	(as it appears on PubMed at http://www.pubmed.gov), where 18163548 is the PubMed ID number.
-	-->
	{{ABSTRACT_PUBMED_18163548}}		{{ABSTRACT_PUBMED_18163548}}

	==About this Structure==		==About this Structure==
-	~~2VIO~~ is a 1 chain structure of sequence from [http://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=2VIO OCA].	+	[[2vio]] is a 1 chain structure of [[Urokinase]] with sequence from [http://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=2VIO OCA].
		+
		+	==See Also==
		+	*[[Urokinase\|Urokinase]]

	==Reference==		==Reference==
-	<ref group="xtra">PMID:~~18163548~~</ref><references group="xtra"/>	+	<ref group="xtra">PMID:018163548</ref><references group="xtra"/>
	[[Category: Homo sapiens]]		[[Category: Homo sapiens]]
	[[Category: U-plasminogen activator]]		[[Category: U-plasminogen activator]]
Line 43:		Line 34:
	[[Category: Inhibitor]]		[[Category: Inhibitor]]
	[[Category: Kringle]]		[[Category: Kringle]]
-	[[Category: Pharmaceutical]]
	[[Category: Phosphorylation]]		[[Category: Phosphorylation]]
	[[Category: Plasminogen activation]]		[[Category: Plasminogen activation]]
-	[[Category: Polymorphism]]
	[[Category: Protease]]		[[Category: Protease]]
	[[Category: Secreted]]		[[Category: Secreted]]
Line 52:		Line 41:
	[[Category: Urokinase-type plasminogen activator]]		[[Category: Urokinase-type plasminogen activator]]
	[[Category: Zymogen]]		[[Category: Zymogen]]
-
-	''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Tue Feb 17 22:03:28 2009''